Chemomab Therapeutics Ltd. CMMB
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 12.72% | 9.85% | 16.07% | 10.94% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -0.93% | -38.56% | -39.97% | -13.86% | |
| Operating Income | 0.93% | 38.56% | 39.97% | 13.86% | |
| Income Before Tax | -5.25% | 36.79% | 43.35% | 14.09% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -5.25% | 36.79% | 43.35% | 14.09% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -5.25% | 36.79% | 43.35% | 14.09% | |
| EBIT | 0.93% | 38.56% | 39.97% | 13.86% | |
| EBITDA | 0.67% | 38.86% | 40.19% | 13.83% | |
| EPS Basic | 23.80% | 61.89% | 65.04% | 46.48% | |
| Normalized Basic EPS | -- | -- | -- | -- | |
| EPS Diluted | 23.80% | 61.89% | 65.04% | 46.48% | |
| Normalized Diluted EPS | -- | -- | -- | -- | |
| Average Basic Shares Outstanding | 38.13% | 65.90% | 62.02% | 60.53% | |
| Average Diluted Shares Outstanding | 38.12% | 65.87% | 61.97% | 60.72% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |